371 related articles for article (PubMed ID: 36549282)
1. Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions.
Estevez-Ordonez D; Gary SE; Atchley TJ; Maleknia PD; George JA; Laskay NMB; Gross EG; Devulapalli RK; Johnston JM
Pediatr Neurosurg; 2023; 58(5):313-336. PubMed ID: 36549282
[TBL] [Abstract][Full Text] [Related]
2. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
4. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
5. The unique immune ecosystems in pediatric brain tumors: integrating single-cell and bulk RNA-sequencing.
Cao L; Xie W; Ma W; Zhao H; Wang J; Liang Z; Tian S; Wang B; Ma J
Front Immunol; 2023; 14():1238684. PubMed ID: 38094301
[TBL] [Abstract][Full Text] [Related]
6. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward.
Mishra DK; Popovski D; Morris SM; Bondoc A; Senthil Kumar S; Girard EJ; Rutka J; Fouladi M; Huang A; Olson JM; Drissi R
Neuro Oncol; 2024 Feb; 26(2):226-235. PubMed ID: 37713135
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for brain tumors: understanding early successes and limitations.
Lieberman NAP; Vitanza NA; Crane CA
Expert Rev Neurother; 2018 Mar; 18(3):251-259. PubMed ID: 29322843
[TBL] [Abstract][Full Text] [Related]
10. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
11. Towards Immunotherapy for Pediatric Brain Tumors.
Wang SS; Bandopadhayay P; Jenkins MR
Trends Immunol; 2019 Aug; 40(8):748-761. PubMed ID: 31229353
[TBL] [Abstract][Full Text] [Related]
12. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
13. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the treatment of pediatric brain tumors: a narrative review.
Shalita C; Hanzlik E; Kaplan S; Thompson EM
Transl Pediatr; 2022 Dec; 11(12):2040-2056. PubMed ID: 36643672
[TBL] [Abstract][Full Text] [Related]
15. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Foster JB; Alonso MM; Sayour E; Davidson TB; Persson ML; Dun MD; Kline C; Mueller S; Vitanza NA; van der Lugt J
Neoplasia; 2023 Aug; 42():100909. PubMed ID: 37244226
[TBL] [Abstract][Full Text] [Related]
16. The therapy of infantile malignant brain tumors: current status?
Kalifa C; Grill J
J Neurooncol; 2005 Dec; 75(3):279-85. PubMed ID: 16195802
[TBL] [Abstract][Full Text] [Related]
17. The current landscape of immunotherapy for pediatric brain tumors.
Hwang EI; Sayour EJ; Flores CT; Grant G; Wechsler-Reya R; Hoang-Minh LB; Kieran MW; Salcido J; Prins RM; Figg JW; Platten M; Candelario KM; Hale PG; Blatt JE; Governale LS; Okada H; Mitchell DA; Pollack IF
Nat Cancer; 2022 Jan; 3(1):11-24. PubMed ID: 35121998
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system.
El Moukhtari SH; Garbayo E; Fernández-Teijeiro A; Rodríguez-Nogales C; Couvreur P; Blanco-Prieto MJ
J Control Release; 2022 Aug; 348():553-571. PubMed ID: 35705114
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
